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Abstract
Rationale: Aside from blood pressure lowering, treatment options for intracerebral haemorrhage remain limited and a
proportion of patients will undergo early haematoma expansion with resultant significant morbidity and mortality.
Tranexamic acid (TXA), an anti-fibrinolytic drug, has been shown to significantly reduce mortality in patients, who are
bleeding following trauma, when given rapidly. TICH-2 is testing whether TXA is effective at improving outcome in
spontaneous intracerebral haemorrhage (SICH).
Methods and design: TICH-2 is a pragmatic, phase III, prospective, double-blind, randomised placebo-controlled trial.
Two thousand adult (aged ≥ 18 years) patients with an acute SICH, within 8 h of stroke onset, will be randomised to
receive TXA or the placebo control. The primary outcome is ordinal shift of modified Rankin Scale score at day 90.
Analyses will be performed using intention-to-treat.
Results: This paper and its attached appendices describe the statistical analysis plan (SAP) for the trial and were
developed and published prior to database lock and unblinding to treatment allocation. The SAP includes details
of analyses to be undertaken and unpopulated tables which will be reported in the primary and key secondary
publications. The database will be locked in early 2018, ready for publication of the results later in the same year.
Discussion: The SAP details the analyses that will be done to avoid bias arising from prior knowledge of the
study findings. The trial will determine whether TXA can improve outcome after SICH, which currently has no
definitive therapy.
Trial registration: ISRCTN registry, ID: ISRCTN93732214. Registered on 17 January 2013.
Keywords: Hyperacute, Spontaneous intracerebral haemorrhage, Tranexamic acid, Randomised trial,
Placebo-controlled
Background
Haemorrhagic stroke or intracerebral haemorrhage (ICH),
caused by bleeding in the brain, can be devastating and is
a common cause of death and disability, both in the UK
and worldwide. Despite development of effective treat-
ments for ischaemic stroke (thrombolysis, aspirin, hemi-
craniectomy, thrombectomy) there is no proven effective
treatment for ICH. Outcome after ICH is closely related
to whether brain bleeding expands after onset, so-called
haematoma expansion, or whether re-bleeding occurs;
both are associated with a poor outcome (death and dis-
ability) [1]. Haematoma expansion is related to both
haemostatic factors and blood pressure; furthermore,
haematoma volume can be reduced surgically. For ICH,
aside from intensive blood pressure lowering, treatment
options remain limited and a proportion of patients will
undergo early haematoma expansion with resultant sig-
nificant morbidity and mortality. An ICH that occurs in
the absence of a known underlying cause, e.g. aneurysm,
arteriovenous malformation (AVM) or tumour, is referred
to as a spontaneous intracerebral haemorrhage (SICH).
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Tranexamic acid (TXA) is a licensed anti-fibrinolytic
drug that can be administered intravenously or orally
and is used in a number of bleeding conditions to re-
duce bleeding [2, 3]. It has been tested in aneurysmal
subarachnoid haemorrhage, where it reduced the risk of
re-bleeding at the expense of increased risk of cerebral
ischaemia [4]; however, administration was for a week,
conferring prolonged exposure to risk of ischaemic
events. In a recent mega-trial (CRASH-2) in 20,000 pa-
tients, with major bleeding following trauma, TXA sig-
nificantly reduced mortality, odds ratio (OR) 0.91 (0.85,
0.97), with no increase in vascular occlusive events [5].
Treatment was most effective when given rapidly; de-
layed administration was associated with lack of efficacy
and potential harm [6]. In another randomised con-
trolled trial in traumatic ICH, TXA showed trends to-
wards reduced death: OR 0.69 (0.35, 1.39), and death or
dependency: OR 0.76 (0.46, 1.27), without increased
thromboembolic events [7]. Additionally, TXA has been
found to restrict haematoma expansion in acute SICH in
a small non-randomised study, although this did not re-
port on safety [8]. In another small study (n = 156), rapid
administration of a bolus of TXA within 24 h of stroke
was observed to reduce haematoma expansion (17.5%
vs. 4.3%) [9]. In this study, TXA was given in combin-
ation with intensive blood pressure control, suggesting
that it may be possible to combine haemostatic and
haemodynamic approaches. There have been recent calls
in the academic literature for large clinical trials to
examine the use of TXA in ICH [10].
The on-going TICH-2 trial is a phase III, prospective,
double-blind, randomised placebo-controlled trial, which
will assess whether TXA (intravenous 1 g bolus, 1 g in-
fusion/8 h) in acute (<8 h) SICH is safe and reduces
death or dependency (measured as a shift in the modi-
fied Rankin Scale (mRS) score). TICH-2 is pragmatic in
design, with minimal inclusion and exclusion criteria.
Further information regarding randomisation can be
found in the protocol [11]. TICH-2 followed a two-
phase design: the 12-month start-up phase (to assess
feasibility) aimed to recruit a minimum of 300 participants
from 30 centres, then the main phase is continuing to re-
cruit to a target of 2000 participants from 120 centres over
43 months. The Independent Data Monitoring Committee
(iDMC) assessed the trial every 6 months and recom-
mended that the trial should continue on each occa-
sion. Whilst recruitment in the UK was ahead of
schedule, recruitment internationally was delayed by
prolonged approval processes. Therefore, a 12-month,
no-cost extension was sought and approved in April
2016 to allow additional time to enable the trial to
reach 2000 participants. Recruitment rate subsequently
increased, with recruitment likely to exceed the original
2000 participant target. The Trial Steering Committee
recommended that recruitment continues until the end
of the allotted funding in order to maximise recruit-
ment, international participants, recruitment into the
magnetic resonance imaging (MRI) sub-study and
statistical power.
Methods and design
The statistical analysis plan (SAP), detailed in Additional
file 1, will ensure that the analyses are not data driven or
selectively reported. Presentation of primary analyses is
expected in spring 2018, after all participants have been
followed up to day 90. Additional file 1 will detail tables
to be included in the primary publication, as well as brief
descriptions of other planned publications.
The primary outcome, death or dependency (ordinal
shift on mRS) at day 90, will be analysed by intention-to-
treat using ordinal logistic regression (OLR), with adjust-
ment for minimisation factors. Whilst there are limitations
to using an ordinal analysis of the mRS score (for example,
moving from a 6 to a 5 may not be perceived as clinically
useful and distances between points are not always
equivalent), this approach is widely accepted across stroke
trials and recommended by the European Stroke Organ-
isation (ESO) Outcomes Working Party [12]. A number of
secondary and sub-group analyses will be undertaken;
time to randomisation is likely to be the most important
sub-group and so will be examined in more detail.
The results will determine whether TXA can improve
outcome after SICH, which currently has no proven
therapy. Three sub-studies are being run in conjunction
with the trial; one for a telephone follow-up at day 365,
one which takes two MRI scans at days 5 and 90 and
the third one is a single-centre sub-study that explores
plasma biomarkers at baseline, day 2, and day 7. A
number of secondary publications are also planned,
including; a paper giving further details on randomisation
and baseline characteristics and a number of papers
addressing secondary outcomes. An individual patient
data meta-analysis is planned; using data from studies that
looked at using TXA for ICH.
Data sharing
Once completed, data from TICH-2 will be added to
summary and individual patient data meta-analyses in
acute stroke. IPD will be made available to the ‘Virtual
International Stroke Trials Archive’ (VISTA) [13], and
subsequently over the web, as with the International
Stroke Trial [14]. Similarly, anonymised baseline and on-
treatment neuroimaging data will be published [15].
Supporting information
Additional supporting information may be found in the
online version of this article. Additional file 1 shows the
SAP (TICH-2).
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Trial status
At the time of first submission the TICH-2 trial was on-
going with recruitment due to finish on 30 September
2017 and with follow-up of the primary outcome on-
going until 30 December 2017.
Additional file
Additional file 1: ‘TICH-2 statistical analysis plan (SAP) appendix V1.6.doc’
includes: Appendix A – SAP; Appendix B – definitions; Appendix C – tables
and figures; Appendix D – secondary publications. (DOCX 611 kb)
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